Dr Steve Kern

Steven E. Kern, PhD is Deputy Director of Quantitative Sciences at the Bill and Melinda Gates Foundation. The Quantitative Sciences group is part of the Integrated Development Function at the Gates Foundation, focused on quantitative analysis to support program strategies for therapeutic projects that the foundation funds. Prior to this, he was Global Head of Pharmacology Modelling at Novartis Pharma AG based in Basel, Switzerland where he lead a team focused on providing model based drug development support to therapeutics in many disease conditions across all stages of drug development. He joined Novartis in 2010 from the University of Utah in Salt Lake City, Utah, USA, where he was Associate Professor of Pharmaceutics, Anesthesiology, and Bioengineering, and served as co-investigator for their NIH funded Pediatric Pharmacology Research Unit. He has designed, conducted, and served as a principal investigator for clinical pharmacology studies in adults and children that spanned the population from preterm infants to elderly adults. Steve has a bachelor’s degree in Mechanical Engineering from Cornell University, USA, a Master’s degree in Bioengineering from Penn State University, USA, and a doctoral degree in Bioengineering from the University of Utah, USA. He has published over 60 papers in areas of pharmacokinetic and pharmacodynamic modelling, applying principles of control systems engineering to drug delivery, and clinical pharmacology.

Steve is the Foundation's Project Officer for the Malaria work of the Diagnostics Modelling Consortium.

Research area(s):